Electrophysiologic effects of ethmozin in patients with ventricular tachycardia

David E. Mann, Jerry C. Luck, John M. Herre, Sharon A. Magro, Sheila C. Yepsen, Jerry C. Griffin, Craig Pratt, Christopher R.C. Wyndham

Research output: Contribution to journalArticlepeer-review

23 Scopus citations


Ten patients with recurrent episodes of ventricular tachycardia (VT) had electrophysiologic studies in the basal state and on chronic oral ethmozin (12.1 ± 0.6 SE mg/kg/day). Ethmozin significantly prolonged the AH interval (basal: 75 ± 8 SE msec; ethmozin: 91 ± 10 msec, p < 0.05), the HV interval (51 ± 3; 66 ± 5 msec, p < 0.01), and the QRS duration (101 ± 4; 118 ± 4 msec, p < 0.001). Atrial and ventricular refractory periods and the corrected QT interval were not significantly affected by ethmozin. VT was induced in 7 of 10 patients in the basal state by means of programmed right ventricular extrastimulation or rapid burst ventricular pacing. On oral ethmozin nine patients had inducible VT. VT cycle length was consistently prolonged on ethmozin (250 ± 13; 326 ± 14 msec, p < 0.001). Four of the seven patients with VT on basal ambulatory monitoring had total abolition of spontaneous VT on ethmozin. Ethmozin failed to prevent induction of VT in most patients despite significant reductions in ventricular arrhythmia on ambulatory monitoring. Further studies comparing VT induction with ambulatory monitoring in patients on ethmozin are needed to confirm these findings and to define the clinical significance of this dissociation.

Original languageEnglish (US)
Pages (from-to)674-679
Number of pages6
JournalAmerican Heart Journal
Issue number4
StatePublished - Apr 1984

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Electrophysiologic effects of ethmozin in patients with ventricular tachycardia'. Together they form a unique fingerprint.

Cite this